Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Non Operating Investment Income (2016 - 2022)

ProQR Therapeutics' Non Operating Investment Income history spans 2 years, with the latest figure at $625130.1 for Q3 2022.

  • On a quarterly basis, Non Operating Investment Income rose 299.28% to $625130.1 in Q3 2022 year-over-year; TTM through Sep 2022 was $3.4 million, a N/A change, with the full-year FY2020 number at $2.0 million, up 548.09% from a year prior.
  • Non Operating Investment Income hit $625130.1 in Q3 2022 for ProQR Therapeutics, up from $128046.8 in the prior quarter.
  • Over the last five years, Non Operating Investment Income for PRQR hit a ceiling of $3.0 million in Q2 2021 and a floor of -$313690.4 in Q3 2021.